The Lancet in conversation with

Presented at ASCO: the first RCT of CAR T-cell therapy in solid tumours


Listen Later

Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer.

Read the full article:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

...more
View all episodesView all episodes
Download on the App Store

The Lancet in conversation withBy The Lancet Group


More shows like The Lancet in conversation with

View all
Consumer Foods to Go by Rabobank

Consumer Foods to Go

5 Listeners

The Lancet Voice by The Lancet Group

The Lancet Voice

23 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Oncology in conversation with by The Lancet Group

The Lancet Oncology in conversation with

1 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

2 Listeners

The Lancet Haematology in conversation with by The Lancet Group

The Lancet Haematology in conversation with

0 Listeners

The Lancet Gastroenterology & Hepatology in conversation with by The Lancet Group

The Lancet Gastroenterology & Hepatology in conversation with

0 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

eClinicalMedicine in conversation with by The Lancet Group

eClinicalMedicine in conversation with

0 Listeners

The Lancet Rheumatology in conversation with by The Lancet Group

The Lancet Rheumatology in conversation with

0 Listeners

The Lancet Regional Health in conversation with by The Lancet Group

The Lancet Regional Health in conversation with

0 Listeners